Blue Owl Capital Holdings’s Ultragenyx Pharmaceutical RARE Stock Holding History

Blue Owl Capital Holdings’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.34M	Buy	302,638 +90,000	+42%	+$2.03M	1.7%	14
2025 Q4	$4.89M	Sell	212,638 -209,800	-50%	-$6.9M	1.51%	21
2025 Q3	$12.7M	Buy	422,438 +167,200	+66%	+$5.01M	3.94%	9
2025 Q2	$9.28M	Buy	255,238 +102,000	+67%	+$3.68M	3%	10
2025 Q1	$5.55M	Buy	153,238 +35,000	+30%	+$1.46M	1.79%	15
2024 Q4	$4.97M	Sell	118,238 -45,000	-28%	-$2.23M	1.15%	20
2024 Q3	$9.07M	Sell	163,238 -105,000	-39%	-$5.35M	1.75%	15
2024 Q2	$11M	Hold	268,238	–	–	3.07%	11
2024 Q1	$12.5M	Buy	268,238 +5,000	+2%	+$236K	2.5%	12
2023 Q4	$12.6M	Buy	+263,238	New	+$10.2M	3.01%	11

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Blue Owl Capital Holdings's RARE Position: Q1 2026 in Review

Blue Owl Capital Holdings increased its Ultragenyx Pharmaceutical (RARE) stake by 42% in Q1 2026, buying an estimated $2.03M and bringing the position to 302,638 shares worth $6.34M. The position accounts for 1.7% of the portfolio, ranked #14.

Blue Owl Capital Holdings first reported a position in RARE in Q4 2023 and has held it in 10 quarters since. The position peaked at $12.7M in Q3 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Blue Owl Capital Holdings held 302,638 shares of Ultragenyx Pharmaceutical worth $6.34M as of Q1 2026.
Blue Owl Capital Holdings bought 90,000 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $2.03M.
Ultragenyx Pharmaceutical made up 1.7% of Blue Owl Capital Holdings's portfolio in Q1 2026, its #14 holding.
Blue Owl Capital Holdings first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and has held it in 10 quarters since.
Blue Owl Capital Holdings's Ultragenyx Pharmaceutical position peaked at $12.7M in Q3 2025.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2026, filed 14 May 2026.